Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.
Jennifer Marie Suga, MD, a medical oncologist at Kaiser Permanente Vallejo Medical Center, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing (NGS) testing of patients with advanced cancers in the community setting.
Suga says that the goals of this project are to address how to increase the utilization of NGS testing and make it more widespread in community oncology practices. One of the practical challenges for testing in the community setting is lack of access at scale; many health care systems and institutions do not have a lot of robust infrastructure and processes to deliver routine broad-spectrum NGS testing for all patients with advanced cancer, according to Suga.
Employing this comprehensive genomic oncology program will hopefully support community oncologists from the time they ordered the test up to when they receive the results to ultimately increase the utilization of NGS in the community setting, Suga explains. To implement this program, Kaiser Permanente partnered with Strata Oncology, who provided a form through their clinical trials protocol for Kaiser to provide the NGS test for community practices. After that, they will work toward implementing a process for ordering the test all the way through interpretation and results.
<< View more of Targeted Oncology's coverage from the 2020 ASCO Virtual Annual Meeting
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More